Kodak's $765M manufacturing loan on the rocks as red flags multiply

5 Financial Red Flags
Kodak, once famous for its cameras, has been rocked by insider trading allegations in recent days. (Pixabay)

Eastman Kodak's unlikely deal with the federal government to dive into drug manufacturing has raised eyebrows—not only for the size of the loan itself but Kodak's lack of experience. Now, with investigations mounting, the U.S. is pumping the brakes. 

The government put the $765 million loan on hold after "allegations of wrongdoing" on the company's part jeopardized its federally funded move into pharmaceuticals, the U.S. International Development Finance Corporation (DFC) said in a terse tweet Friday. 

Kodak and the DFC signed an interest letter in late July for a loan that would have jumpstarted Kodak's move into manufacturing active pharmaceutical ingredients (API) for a range of  generic drugs.

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

The government's interest in Kodak—a photography company that declared bankruptcy in 2012 and has limited experience in drugmaking—as well as insider trading allegations spurred a growing number of investigations in recent days. 

Late last week, a group of influential House Democrats sought documents on the DFC loan, arguing that Kodak didn't appear to have the needed experience to qualify for the massive funding deal. 

RELATED: House Dems launch probe into Kodak's unexpected $765M drug manufacturing loan from the feds

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.